Oncology Institute Statistics
Share Statistics
Oncology Institute has 75.56M shares outstanding. The number of shares has increased by 2.36% in one year.
| Shares Outstanding | 75.56M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.41% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 36.77M |
| Failed to Deliver (FTD) Shares | 1 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 247.97K, so 0.33% of the outstanding shares have been sold short.
| Short Interest | 247.97K |
| Short % of Shares Out | 0.33% |
| Short % of Float | 0.67% |
| Short Ratio (days to cover) | 3.38 |
Valuation Ratios
The PE ratio is -1.81 and the forward PE ratio is -1.73.
| PE Ratio | -1.81 |
| Forward PE | -1.73 |
| PS Ratio | 0.46 |
| Forward PS | 0 |
| PB Ratio | 2.64 |
| P/FCF Ratio | -3.68 |
| PEG Ratio | n/a |
Enterprise Valuation
Oncology Institute Inc. has an Enterprise Value (EV) of 236.77M.
| EV / Earnings | -2.85 |
| EV / Sales | 0.73 |
| EV / EBITDA | -3.36 |
| EV / EBIT | -3.07 |
| EV / FCF | -5.79 |
Financial Position
The company has a current ratio of 4.12, with a Debt / Equity ratio of 1.52.
| Current Ratio | 4.12 |
| Quick Ratio | 3.73 |
| Debt / Equity | 1.52 |
| Total Debt / Capitalization | 60.36 |
| Cash Flow / Debt | -0.42 |
| Interest Coverage | -11.36 |
Financial Efficiency
Return on equity (ROE) is -1.46% and return on capital (ROIC) is -43.57%.
| Return on Equity (ROE) | -1.46% |
| Return on Assets (ROA) | -0.4% |
| Return on Capital (ROIC) | -43.57% |
| Revenue Per Employee | 405.30K |
| Profits Per Employee | -103.83K |
| Employee Count | 800 |
| Asset Turnover | 1.55 |
| Inventory Turnover | 19.35 |
Taxes
| Income Tax | -36.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -83.7% in the last 52 weeks. The beta is 0.62, so Oncology Institute 's price volatility has been higher than the market average.
| Beta | 0.62 |
| 52-Week Price Change | -83.7% |
| 50-Day Moving Average | 0.26 |
| 200-Day Moving Average | 0.64 |
| Relative Strength Index (RSI) | 53.32 |
| Average Volume (20 Days) | 1.61M |
Income Statement
In the last 12 months, Oncology Institute had revenue of $324.24M and earned -$83.07M in profits. Earnings per share was $-0.92.
| Revenue | 324.24M |
| Gross Profit | 59.57M |
| Operating Income | -77.02M |
| Net Income | -83.07M |
| EBITDA | -70.45M |
| EBIT | -77.02M |
| Earnings Per Share (EPS) | -0.92 |
Balance Sheet
The company has $33.49M in cash and $119.67M in debt, giving a net cash position of -$86.19M.
| Cash & Cash Equivalents | 33.49M |
| Total Debt | 119.67M |
| Net Cash | -86.19M |
| Retained Earnings | -146.15M |
| Total Assets | 179.18M |
| Working Capital | 69.67M |
Cash Flow
In the last 12 months, operating cash flow was -$36.31M and capital expenditures -$4.57M, giving a free cash flow of -$40.88M.
| Operating Cash Flow | -36.31M |
| Capital Expenditures | -4.57M |
| Free Cash Flow | -40.88M |
| FCF Per Share | -0.55 |
Margins
Gross margin is 18.37%, with operating and profit margins of -23.75% and -25.62%.
| Gross Margin | 18.37% |
| Operating Margin | -23.75% |
| Pretax Margin | -25.63% |
| Profit Margin | -25.62% |
| EBITDA Margin | -21.73% |
| EBIT Margin | -23.75% |
| FCF Margin | -12.61% |
Dividends & Yields
TOI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -418.18% |
| FCF Yield | -242.08% |
Analyst Forecast
The average price target for TOI is $2.5, which is 1036.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.5 |
| Price Target Difference | 1036.4% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -0.18 |
| Piotroski F-Score | 2 |